Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Breast Cancer

Title: Clinical breast cancer

Publisher: Elsevier BV

ISSN (Electronic): 1938-0666

ISSN (Print): 1526-8209

Publication date (Electronic): Feb 2021

Volume: 21

Issue: 1

Affiliations

[1 ] Breast Clinical Trials Unit, Breast Cancer Research Centre-WA & Curtin University, Perth, Australia. Electronic address: arlenechan@me.com.

[2 ] Breast Oncology Program, Massachusetts General Hospital Cancer Center, Boston, MA.

[3 ] Oncology & Haematology Clinical Trials, Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom.

[4 ] Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

[5 ] Texas Oncology/US Oncology Research, Houston, TX.

[6 ] Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.

[7 ] Clinical Oncology, Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.

[8 ] Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

[9 ] Center for Hematology and Oncology Bethanien, Frankfurt, Germany.

[10 ] Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.

[11 ] Department of Oncology, Dokuz Eylul Universitesi Tip Fakultesi Hastanesi Tibbi Onkoloji Anabilim Dali Mithatpaşa, Balçova, Izmir, Turkey.

[12 ] University Clinic for Radiotherapy and Oncology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.

[13 ] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

[14 ] Oncología Médica, Hospital Universitario Nuestra Señora de la Candelaria Ctra. Del Rosario, Sta. Cruz De Tenerife, Canarias.

[15 ] Breastlink Medical Group, Inc, Santa Ana, CA.

[16 ] Division of Hematology/Oncology, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Nashville, TN.

[17 ] Onkologisk Afdeling R, Odense University Hospital, Odense, Denmark.

[18 ] Hospital Universitario Arnau Vilanova Servei d'Oncologia Mèdica i Hematologia, Lleida, Spain.

[19 ] Physician Medical Center, Northwest Medical Specialties PLLC, Tacoma, WA.

[20 ] Breast Oncology, Saitama Cancer Center, Kita-Adachi, Japan.

[21 ] Oncología, Hospital Universitario Virgen del Rocio, Seville, Spain.

[22 ] Crown Princess Mary Cancer Centre, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.

[23 ] Virginia Cancer Specialists, Arlington, VA.

[24 ] Texas Oncology - Round Rock, Austin, TX.

[25 ] Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, CA.

[26 ] The Breast Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.

[27 ] Puma Biotechnology Inc., Los Angeles, CA.

[28 ] Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain.

Article

Publisher Item ID: S1526-8209(20)30258-5

DOI: 10.1016/j.clbc.2020.09.014

PubMed ID: 33183970

SO-VID: 17d57605-5f96-4569-90ab-0e27f26104be

History

Keywords: Adjuvant therapy,Disease-free survival,Distant disease-free survival,Neoadjuvant therapy,Overall survival

Data availability:

Keywords: Adjuvant therapy, Disease-free survival, Distant disease-free survival, Neoadjuvant therapy, Overall survival

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

Read this article at

Abstract

Related collections

Efficacy of Communicating Science

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 73

Cited by 75